<DOC>
	<DOCNO>NCT01577862</DOCNO>
	<brief_summary>Acinetobacter baumannii cause severe infection ( pneumonia , bacteremia , organ space ) high lethality hospitalise critically ill patient . It acquire resistance class antibiotic ( multidrug resistance , MDR ) except 'old ' drug , colistin , may therapeutic option . However , colistin register indication . The addition rifampicin colistin show synergistic vitro , may promise vivo , combination study comparison colistin alone . The purpose randomise , open-label , multicentre clinical trial ass whether association colistin rifampicin reduce significantly mortality patient severe MDR A. baumannii infection compare colistin alone . The trial enroll 210 patient intensive care unit ( ICU ) five tertiary care hospital MDR A. baumannii infection endemic epidemic phase . Patients randomly allocate either colistin alone ( control arm ) colistin plus rifampicin ( experimental arm ) . Primary end point overall mortality , define death occur within 30 day randomisation . Secondary end point disease-specific death , microbiological eradication , hospitalization length , emergence resistance colistin treatment .</brief_summary>
	<brief_title>Colistin Rifampicin MDR-Acinetobacter</brief_title>
	<detailed_description>This study design multicentre open-label , parallel randomise , control trial . Patients randomly allocate two treatment arm : 1 ) colistin alone ( control arm ) ; 2 ) colistin , plus rifampicin ( experimental arm ) . The study carry 2 year accord principle good clinical practice . The study population represent adult hospitalise patient severe nosocomial infection due multi-drug resistant A. baumannii , susceptible colistin . It perform intensive sub-intensive care unit 5 Italian clinical centre MDR A. baumannii infection endemic epidemic phase . All adult subject , irrespective age , include study , thus also elderly subject eligible . Large eligibility criterion warrant pragmatic approach study , severe prognosis patient lack effective alternative treatment . Enrollment procedure : At time A. baumannii isolation , inclusion exclusion criterion check pertinent centre . Once obtain informed consent , subject randomize treatment . No patient may enrol centre formal approval Ethics Committee Institution . Accrual time : accord sample size estimate ( see ) base current incidence MDR A. baumannii severe infection 12-14 case per month five participating centre , accrual time last approximately 18 month achieve plan sample size . Severe infection include hospital acquire pneumonia ( HAP ) , ventilator associate pneumonia ( VAP ) , bloodstream infection , intra-abdominal infection organ-space infection . Multi-drug resistant A. baumannii define clinical isolates resistant carbapenems antimicrobial drug class , except colistin , irrespective rifampicin activity . Severity illness assess SAPS II score . This consider low high accord SAPS II score below/equal high 40 , respectively . Patients randomly allocate two treatment arm : 1 ) colistin alone , 2 million unit every 8 hour intravenously accord renal function ( control arm ) ; 2 ) colistin , 2 million unit every 8 hour intravenously accord renal function , plus rifampicin , 600 mg every 12 hour intravenously ( experimental arm ) . Treatment administer least 10 day maximum 21 day . Duration treatment establish physician charge . The end treatment ( EoT ) evaluation perform day treatment discontinuation . The end study ( EoS ) ( follow-up ) evaluation perform 30 day randomization . Treatment discontinue follow instance : clinical cure without microbiological eradication ; occurrence significant renal liver toxicity ; patient death . Throughout study , patient receive routine intensive care support physician charge accord standard diagnostic therapeutic guideline . Clinical cure define disappearance symptom sign infection , irrespective A. baumannii eradication site infection . Therapeutic failure define worsen improvement clinical condition therapy persistently positive A. baumannii culture . Renal liver function monitor daily measurement creatinine , aminotransferase direct bilirubin serum level . Drug dosages adjust accord renal liver function . Renal toxicity define decrease creatinine clearance 50 ml/min &gt; 50 % reduction creatinine clearance relative baseline . Hepatic toxicity define increase direct bilirubin 3 mg/dl . Surveillance culture original source isolation ( blood , bronchial aspirate , urines drainage fluid ) obtain admission repeat weekly , whenever clinically need , treatment monitor persistence versus eradication A. baumannii infect site . In vitro activity colistin rifampicin check A. baumannii repeat isolates detect development resistance . Identification antibiotic susceptibility A. baumannii isolates perform centre use automated system . Species identification confirm molecular biology .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>clinical microbiological evidence severe infection due multidrug resistant A. baumannii hospitalization susceptibility A. baumannii isolate colistin ( MIC &lt; =2 mg/l ) . age 18 year treatment one study drug prior diagnosis A. baumannii infection severe liver dysfunction history prior hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ACINETOBACTER BAUMANNII</keyword>
	<keyword>COLISTIN</keyword>
	<keyword>RIFAMPICIN</keyword>
	<keyword>THERAPY</keyword>
	<keyword>RESISTANCE</keyword>
</DOC>